Protalix BioTherapeutics to Release Q2 2024 Results on August 14, 2024

Protalix BioTherapeutics, Inc., a company dedicated to developing, producing, and commercializing recombinant therapeutic proteins through its proprietary ProCellEx® plant cell-based protein expression system, is set to unveil its financial results for the quarter ending June 30, 2024. The announcement will be accompanied by a comprehensive business and clinical update on August 14, 2024.

The management team will conduct a conference call to discuss these financial results and provide insights into recent corporate and regulatory developments. The call is scheduled for Wednesday, August 14, 2024, at 8:30 a.m. Eastern Daylight Time (EDT). Participants in the U.S. can join the call toll-free at 1-877-423-9813, while international participants can dial in at 1-201-689-8573. Israeli participants can join toll-free at 1-809-406-247. The conference ID for the call is 13747744.

To streamline the process, the "Call me™" feature allows participants to enter their phone number on the platform, and the system will call them directly, bypassing the need to wait for an operator. Additionally, a webcast of the conference call will be available through the company's website. Participants are advised to access the call at least 15 minutes before the scheduled start time to register and download any necessary audio software. A two-week replay of the call will be accessible on the Events Calendar in the Investors section of the company's website.

Protalix BioTherapeutics is notable for being the first company to receive U.S. Food and Drug Administration (FDA) approval for a protein produced using a plant cell-based suspension expression system. This innovation marks a significant advancement in the industrial-scale production of recombinant proteins. The company has licensed the global development and commercialization rights of its first product, taliglucerase alfa, for the treatment of Gaucher disease to Pfizer Inc., retaining full rights only in Brazil.

The company's second product, Elfabrio®, received approval from both the FDA and the European Medicines Agency in May 2023. Protalix has partnered with Chiesi Farmaceutici S.p.A. to handle the global development and commercialization of Elfabrio. This partnership underscores Protalix's commitment to advancing its pipeline, which includes proprietary versions of recombinant therapeutic proteins aimed at established pharmaceutical markets.

Among the promising product candidates in Protalix's development pipeline are PRX-115, a plant cell-expressed recombinant PEGylated uricase intended for treating uncontrolled gout, and PRX-119, a plant cell-expressed long-action DNase I for the treatment of NETs-related diseases. These innovative treatments highlight the company's dedication to addressing unmet medical needs and expanding its footprint in the biopharmaceutical industry.

Protalix's proprietary ProCellEx® system represents a novel approach to developing and producing therapeutic proteins. By leveraging plant cell-based technology, the company aims to offer safer, more cost-effective, and scalable solutions for various medical conditions. The success of this platform is evidenced by the regulatory approvals and strategic partnerships that Protalix has secured.

In summary, Protalix BioTherapeutics continues to make significant strides in the biopharmaceutical field, driven by its innovative ProCellEx® expression system and a robust pipeline of therapeutic proteins. The upcoming financial results announcement and business update on August 14, 2024, will provide further insights into the company's progress and future direction.